insights_auto
Miks on MVIR tõusnud? 5,77%?
Uurige põhjalikumaltchevron_right
MVIR:STO
Medivir AB
1,69 SEK
arrow_upward
+5,77%(+0,092) 1 p
2. okt, 17:29:51 GMT +2 · SEK
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse MVIR põhistatistika genereerimine…
Ava
1,71 SEK
Kõrge
1,78 SEK
Madal
1,67 SEK
Turu kapit.
1,05 mld
Keskm. maht
1,88 mln
Maht
0,00
52 näd kõrgeim
2,88 SEK
52 näd madalaim
0,34 SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18 mln
Töötajate arv
6
Ava
1,71 SEK
Kõrge
1,78 SEK
Madal
1,67 SEK
Turu kapit.
1,05 mld
Keskm. maht
1,88 mln
Maht
0,00
52 näd kõrgeim
2,88 SEK
52 näd madalaim
0,34 SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18 mln
Töötajate arv
6
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
16 minuti eest
Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
Yahoo Finance
·
43 minuti eest
Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew
Simply Wall Street
·
16 minuti eest
3 U.S. Consumer Stocks That Could Benefit If Stimulus Checks Return
USA Today
·
11 tunni eest
Is a stock market correction coming? Most Americans think so
Profiil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Teave üksuse Medivir AB kohta